MetaVia Inc.
MTVA
Helyezés a részvények között
#33006
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Részvényárfolyam
$1.24
Utolsó szinkronizálás: 2026-10-19
Piaci kapitalizáció
$8.17M
Változás (1 nap)
-1.59%
Változás (1 év)
-23.93%
Ország
US
Kereskedés MetaVia Inc. (MTVA)
Kategória
Healthcare
EPS MetaVia Inc. (MTVA) részvényre
EPS June 2026 dátummal, TTM: $-8.42
MetaVia Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $-8.42. 2023 végén a vállalat EPS mutatója $-2.46 volt, növekedés a 2022 év EPS értékéhez, amely $-19.01 volt.
MetaVia Inc. EPS története 2014 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $-8.42 | 136.52% |
| 2024 | $-3.56 | 44.72% |
| 2023 | $-2.46 | -87.06% |
| 2022 | $-19.01 | -87.96% |
| 2021 | $-157.85 | -64.06% |
| 2020 | $-439.20 | -57.38% |
| 2019 | $-1.03K | 517.81% |
| 2018 | $-166.80 | -93.11% |
| 2017 | $-2.42K | 28.59% |
| 2016 | $-1.88K | 47.42% |
| 2015 | $-1.28K | 2,721.85% |
| 2014 | $-45.27 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| $17.32 | -305.70% |
US
|
|
| $-7.98 | -5.23% |
US
|
|
| $-5.29 | -37.17% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -429.45% |
NL
|
